AU2020304001B2 - Solid forms of tert-butyl (S)-2-((2S,3R) -1-amino-3-hydroxy-1-oxobu tan-2-yl)-1-oxo-2, 5-diazaspiro [3.4] octan e-5-carboxylate and methods of preparing them - Google Patents
Solid forms of tert-butyl (S)-2-((2S,3R) -1-amino-3-hydroxy-1-oxobu tan-2-yl)-1-oxo-2, 5-diazaspiro [3.4] octan e-5-carboxylate and methods of preparing themInfo
- Publication number
- AU2020304001B2 AU2020304001B2 AU2020304001A AU2020304001A AU2020304001B2 AU 2020304001 B2 AU2020304001 B2 AU 2020304001B2 AU 2020304001 A AU2020304001 A AU 2020304001A AU 2020304001 A AU2020304001 A AU 2020304001A AU 2020304001 B2 AU2020304001 B2 AU 2020304001B2
- Authority
- AU
- Australia
- Prior art keywords
- crystalline form
- compound
- peaks
- solid crystalline
- chosen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962865826P | 2019-06-24 | 2019-06-24 | |
| US62/865,826 | 2019-06-24 | ||
| PCT/US2020/039163 WO2020263847A1 (en) | 2019-06-24 | 2020-06-23 | Solid forms of tert-butyl (s)-2-((2s,3r) -1-amino-3-hydroxy-1-oxobu tan-2-yl)-1-oxo-2, 5-diazaspiro [3.4] octan e-5-carboxylate and methods of preparing them |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2020304001A1 AU2020304001A1 (en) | 2022-01-27 |
| AU2020304001B2 true AU2020304001B2 (en) | 2026-04-09 |
Family
ID=74060350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020304001A Active AU2020304001B2 (en) | 2019-06-24 | 2020-06-23 | Solid forms of tert-butyl (S)-2-((2S,3R) -1-amino-3-hydroxy-1-oxobu tan-2-yl)-1-oxo-2, 5-diazaspiro [3.4] octan e-5-carboxylate and methods of preparing them |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220267341A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3986399A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7617043B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20260061467A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114364380A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020304001B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021026380A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3144600A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL289198A (cg-RX-API-DMAC7.html) |
| MA (1) | MA56550A (cg-RX-API-DMAC7.html) |
| MX (2) | MX2022000069A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020263847A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI887245B (zh) * | 2019-06-24 | 2025-06-21 | 美商諾雷克斯股份有限公司 | 用於產生二氮雜螺內醯胺化合物之方法及中間物 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014120786A1 (en) * | 2013-01-29 | 2014-08-07 | Naurex, Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| US9512134B2 (en) * | 2013-01-29 | 2016-12-06 | Aptinyx, Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
| WO2017201283A1 (en) * | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0323204D0 (en) * | 2003-10-03 | 2003-11-05 | Novartis Ag | Organic compounds |
| ES2416354T3 (es) * | 2005-06-21 | 2013-07-31 | Ajinomoto Co., Inc. | Cristal de derivado de fenilalanina, método de producción del mismo y uso del mismo |
| MX2011003015A (es) * | 2008-09-18 | 2011-11-18 | Univ Northwestern | Moduladores del receptor de n-metil-d-aspartato, y usos de los mismos. |
| TWI738748B (zh) * | 2016-03-28 | 2021-09-11 | 日商武田藥品工業有限公司 | 2-[(2s)-1-氮雜雙環[2.2.2]辛-2-基]-6-(3-甲基-1h-吡唑-4-基)噻吩并[3,2-d]嘧啶-4(3h)-酮半水合物之晶形 |
| TWI887245B (zh) * | 2019-06-24 | 2025-06-21 | 美商諾雷克斯股份有限公司 | 用於產生二氮雜螺內醯胺化合物之方法及中間物 |
-
2020
- 2020-06-23 BR BR112021026380A patent/BR112021026380A2/pt unknown
- 2020-06-23 EP EP20832010.1A patent/EP3986399A4/en active Pending
- 2020-06-23 JP JP2021576883A patent/JP7617043B2/ja active Active
- 2020-06-23 MA MA056550A patent/MA56550A/fr unknown
- 2020-06-23 US US17/621,907 patent/US20220267341A1/en active Pending
- 2020-06-23 KR KR1020267012575A patent/KR20260061467A/ko active Pending
- 2020-06-23 CN CN202080059974.0A patent/CN114364380A/zh active Pending
- 2020-06-23 MX MX2022000069A patent/MX2022000069A/es unknown
- 2020-06-23 WO PCT/US2020/039163 patent/WO2020263847A1/en not_active Ceased
- 2020-06-23 AU AU2020304001A patent/AU2020304001B2/en active Active
- 2020-06-23 KR KR1020227002351A patent/KR102958083B1/ko active Active
- 2020-06-23 CA CA3144600A patent/CA3144600A1/en active Pending
-
2021
- 2021-12-21 IL IL289198A patent/IL289198A/en unknown
-
2022
- 2022-01-03 MX MX2025002579A patent/MX2025002579A/es unknown
-
2025
- 2025-01-06 JP JP2025001914A patent/JP7858096B2/ja active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014120786A1 (en) * | 2013-01-29 | 2014-08-07 | Naurex, Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| US9512134B2 (en) * | 2013-01-29 | 2016-12-06 | Aptinyx, Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
| WO2017201283A1 (en) * | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114364380A (zh) | 2022-04-15 |
| JP2022539342A (ja) | 2022-09-08 |
| WO2020263847A1 (en) | 2020-12-30 |
| MX2025002579A (es) | 2025-04-02 |
| US20220267341A1 (en) | 2022-08-25 |
| MA56550A (fr) | 2022-04-27 |
| EP3986399A4 (en) | 2023-06-07 |
| AU2020304001A1 (en) | 2022-01-27 |
| EP3986399A1 (en) | 2022-04-27 |
| JP7617043B2 (ja) | 2025-01-17 |
| CA3144600A1 (en) | 2020-12-30 |
| IL289198A (en) | 2022-02-01 |
| MX2022000069A (es) | 2022-05-24 |
| KR20260061467A (ko) | 2026-05-06 |
| KR20220061088A (ko) | 2022-05-12 |
| JP7858096B2 (ja) | 2026-05-13 |
| BR112021026380A2 (pt) | 2022-05-10 |
| JP2025069143A (ja) | 2025-04-30 |
| KR102958083B1 (ko) | 2026-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2970123B1 (en) | Salt of omecamtiv mecarbil and process for preparing salt | |
| EP3889147A1 (en) | 4-({(2s)-2-[4-{5-chloro-2-[4-(trifluoromethyl)-1h-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2h)-yl]butanoyl}-amino)-2-fluorobenzamide acetone and its use | |
| KR102162208B1 (ko) | 7-((3s,4s)-3-[(사이클로프로필아미노)메틸]-4-플루오로피롤리딘-1-일)-6-플루오로-1-(2-플루오로에틸)-8-메톡시-4-옥소-1,4-다이하이드로퀴놀린-3-카복실산 결정 | |
| JP6471103B2 (ja) | ヒスタミンh4受容体のベンゾイミダゾール−2−イルピリミジンモジュレータ | |
| EP2985277A1 (en) | Dipyrromethene crystal and method for manufacturing same | |
| EP2791141B1 (en) | Tofacitinib mono-tartrate salt | |
| CA2768553C (en) | Anhydrate of tiotropium bromide | |
| JP5635181B2 (ja) | ニトロイミダゾール系化合物、その製造方法および用途 | |
| KR20100103427A (ko) | 아연 분말을 이용한 메로페넴의 개선된 제조방법 | |
| US11584715B2 (en) | Crystalline form of sofpironium bromide and preparation method thereof | |
| JP7858096B2 (ja) | tert-ブチル(S)-2-((2S,3R)-1-アミノ-3-ヒドロキシ-1-オキソブタン-2-イル)-1-オキソ-2,5-ジアザスピロ[3.4]オクタン-5-カルボキシレートの固体形態およびそれらを調製する方法 | |
| KR102768447B1 (ko) | (-)-시벤졸린 숙신산염의 신규한 제조 공정 | |
| AU2020210998A1 (en) | Crystal form of 1,2,3-triazolo(1,5-a)pyrazines derivative and preparation method for crystal form | |
| WO2025029842A2 (en) | Process of making 2-[(3r)-2-[4-amino-3-(2-fluoro-4-phenoxy- phenyl)pyrazolo[3,4-d]pyrimidin-l-yl]piperidine-l-carbonyl]-4- methyl-4[4-(oxetan-3-yl)piperazin-l-yl]-pent-2-enenitrile and solvate forms thereof | |
| US20120220655A1 (en) | Crystalline forms of fesoterodine fumarate and fesoterodine base | |
| EA044016B1 (ru) | Твердые формы трет-бутил(s)-2-((2s,3r)-1-амино-3-гидрокси-1-оксобутан-2-ил)-1-оксо-2,5-диазаспиро[3.4]октан-5-карбоксилата и способы их получения | |
| HK40068368B (en) | Crystalline form of sofpironium bromide and preparation method thereof | |
| KR20240135640A (ko) | 뉴로키닌-1 길항제 전구약물 화합물의 결정형 | |
| HK40068368A (en) | Crystalline form of sofpironium bromide and preparation method thereof | |
| AU2019250339A1 (en) | Polymorph of sodium neridronate and preparation process thereof | |
| US8569289B2 (en) | Fumarate salt of 4-bromophenyl 1,4-diazabicyclo[3.2.2]nonane-4-carboxylate, crystalline forms thereof, preparation thereof and therapeutic use thereof | |
| HK1218544B (en) | Salt of omecamtiv mecarbil and process for preparing salt | |
| JP2012500192A (ja) | 1−イソプロピル−4−{[4−(テトラヒドロ−2h−ピラン−4−イルオキシ)フェニル]カルボニル}ヘキサヒドロ−1h−1,4−ジアゼピンの塩およびその調製方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |